In advanced cutaneous T-cell lymphoma (CTCL), allogeneic stem cell transplant is the only curative option, but many patients are ineligible and relapse after systemic therapy, requiring retreatment with prior therapies. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody drug conjugated with monomethyl auristati...
C. Mitteldorf, A. de Masson, M. Beylot-Barry et al.· Leukemia and Lymphoma· 0 citations
BACKGROUND
Mogamulizumab, an anti-CCR4 monoclonal antibody used in advanced mycosis fungoides (MF) and Sezary syndrome (SS), also depletes regulatory T cells, potentially leading to immune-related adverse events (irAEs). Unlike mogamulizumab-associated rash (MAR), other irAEs remain poorly documented to date.
OBJECTI...
David Neubauer, P. Palassin, C. Ram-Wolff et al.· Journal of the European Acad...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.